GENESIS Study



Patient Information

The GENESIS Pregnancy Registry is for pregnant women diagnosed with migraine who have (or have not) taken Aimovig® (erenumab-aooe) shortly before or during pregnancy.

The information in this brochure should help you decide whether you or someone you know may want to join the registry.

What is an observational study?

The purpose of an observational study (a type of medical research study) is to learn more about approved medications and how they are used. The GENESIS Pregnancy Registry is an observational study.

When choosing to take part in an observational study, it is important to understand why it is taking place and what it will involve.

The GENESIS Pregnancy Registry is looking for pregnant women diagnosed with migraine who have (or have not) taken Aimovig® (erenumab-aooe) shortly before or during their pregnancy.

If you take part in the GENESIS Pregnancy Registry, the registry team will receive information about your and your baby's medical appointments. Your personal information (for example, age and date of birth), together with any health information collected about you or your baby, will be kept private. You will not need to attend any additional medical appointments or take any additional medications.



About the GENESIS Pregnancy Registry



Aimovig is a medication that has been approved by the US Food and Drug Administration (FDA) for the preventive treatment of migraine in adults. This registry has been created to help doctors better understand if Aimovig has any effect on a woman's pregnancy, delivery, or baby. You do **not** need to have taken Aimovig to participate.

Why is the GENESIS Pregnancy Registry important?

Often when a pregnant woman takes a medication, the effect of that medication on the health of her unborn baby is not usually known. This is because pregnant women are often not included in most research studies. Pregnancy registries are designed to help healthcare providers learn more about medications and the potential effects on babies.

The GENESIS Pregnancy Registry will collect information about how pregnancies and babies may, or may not, be affected by Aimovig.

What will the GENESIS Pregnancy Registry involve?

If you take part, you will be in the registry throughout your pregnancy and 1 year after your delivery.

You will need to:

- talk to the registry team on the phone and answer questions about your health, lifestyle, pregnancy, and your baby's health
- agree for you, your doctor, and your baby's doctor to give information about your health, pregnancy, and delivery, and information on your baby's health, to the registry team.

The phone calls will take place:

- every trimester
- 4 weeks after your delivery, and
- when your baby is 3 months, 6 months, and 1 year old.

Who can take part?

You may be able to participate if you have been diagnosed with migraine, are currently pregnant, and:

- ☑ have taken Aimovig during the 16 weeks (about 4 months) before your last menstrual period and/or any time during pregnancy, **or**
- ☑ have **not** taken Aimovig or any medication targeting the calcitonin gene-related peptide (CGRP) pathway, including Ajovy® (fremanezumab-vfrm) and Emgality® (galcanezumab-gnlm), shortly before or during your pregnancy, **and**
- ☑ agree for you, your doctor, and your baby's doctor to provide information about your health, pregnancy, and delivery, and information on your baby's health, to the registry team.

What else do I need to consider?

- You do not have to join the registry if you do not want to.
- If you choose to take part in the registry, you can stop participating at any time.
- The first phone call that participants will have with the registry team may take up to 45 minutes. The rest of the calls are expected to last for about 10–15 minutes each.
- You will not be required to take any medications or have any additional visits that are not part of your regular care.

How do I get more information?

If you are currently pregnant and taking Aimovig® (erenumab-aooe), contact your healthcare provider. They will decide if you should stop taking Aimovig®.

To find out more, please call a GENESIS Pregnancy Registry representative at 1 (833) 244-4083 (toll free) or visit **www.genesispregnancyregistry.com.**

Your participation in the registry is voluntary. By contacting us, you are under no obligation to take part.



Patient Brochure,
06 Jan 2021 [V01 USA(en)]